Oct. 9 at 10:21 AM
Citizens⬆️the PT on
$AQST to
$12 from
$9, reiterated at a Market Outperform and said that expanded patent protection provides high confidence in Anaphylm's exclusivity through at least 2037
$SPRY $TEVA $VTRS
Citizens JMP added, Yesterday, Aquestive announced the issuance of two additional patents for Anaphylm, extending brand exclusivity through at least 2037. We view these patents as meaningfully value accretive as they cover compositions of matter for the novel epinephrine prodrug used in the product candidate. As such, we update our model to project sales through YE2037 (vs. 2034 prior), which drives our increased price target.